New Advances in Relapsed/Refractory Multiple Myeloma: Frequently Asked Questions on Current and Emerging Treatments

In this episode, Natalie S. Callander, MD, and Shaji Kumar, MD, answer audience questions from a live CCO Webinar on relapsed/refractory myeloma regarding challenges in treating patients in this setting, including optimizing treatment choices and sequencing of treatments, MRD testing in myeloma, promising BCMA-targeted agents, the promise and value of CAR T-cell therapy in myeloma, and more.

Presenters:

Natalie S. Callander, MD
Professor of Medicine  
Director, Myeloma Clinical Program  
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

Shaji Kumar, MD
Department of Hematology
Mayo Clinic
Rochester, Minnesota

Content based on an online CME program supported by educational grants from GlaxoSmithKline LLC and Sanofi Genzyme.

Link to full program, including associated downloadable slidesets:

 https://bit.ly/3gT324y

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.